Loading organizations...
§ Private Profile · Niel, Antwerpen, Belgium
mRNA and LNP technology platform company developing and licensing mRNA-based therapeutics and vaccines for biopharma partners.
Founded in 2013, etherna is a private mRNA and lipid nanoparticle technology platform company based in Niel, Belgium, with an additional research center located near Boston. Led by Chief Executive Officer Bernard Sagaert and Chairman Marijn Dekkers, the organization employs over 75 team members and generates approximately $14.8 million in revenue. The firm licenses its proprietary molecular designs and customized lipid formulations to biopharma partners developing next-generation therapeutics and vaccines for cancer, infectious diseases, heart conditions, and kidney diseases. Backed by investors like Novalis LifeSciences, the biotechnology enterprise has raised $103.7 million in total funding across multiple rounds, while its board includes Moderna co-founder Kenneth Chien. In January 2025, the company established a major strategic collaboration with Dropshot Therapeutics that includes upfront payments, research funding, and milestone payments potentially valued at up to $950 million.
etherna immunotherapies has raised $104.4M across 3 funding rounds.
etherna immunotherapies has raised $104.4M in total across 3 funding rounds.
etherna immunotherapies has raised $104.4M in total across 3 funding rounds.
etherna immunotherapies's investors include Citi Ventures, Early Light Ventures, EQT Life Sciences, Humba Ventures, Lerer Hippeau, Matchstick Ventures, Pareto Holdings, TTV Capital, Y Combinator, Jett McCandless, BNP Paribas Fortis Private Equity, Boehringer Ingelheim.
etherna immunotherapies has raised $104.4M across 3 funding rounds. Most recently, it raised $39.0M Series B in August 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Aug 1, 2022 | $39M Series B | — | Citi Ventures, Early Light Ventures, EQT Life Sciences, Humba Ventures, Lerer Hippeau, Matchstick Ventures, Pareto Holdings, TTV Capital, Y Combinator, Jett Mccandless | Announced |
| Jun 16, 2020 | $38.4M Series B | — | BNP Paribas Fortis Private Equity, Boehringer Ingelheim, Fund+, Grand Decade, LSP, Novalis LifeSciences, Omega Funds, PMV, Yijing Capital | Announced |
| Mar 1, 2016 | $27M Series A | — | Citi Ventures, Early Light Ventures, EQT Life Sciences, Humba Ventures, Lerer Hippeau, Matchstick Ventures, Pareto Holdings, TTV Capital, Y Combinator, Jett Mccandless | Announced |
# eTheRNA Immunotherapies: A Technology Company Pioneering mRNA-Based Therapeutics
eTheRNA Immunotherapies is a Belgian biotech company specializing in mRNA technology platforms for developing immunotherapies targeting cancer and infectious diseases.[2] Founded in 2013 as a spin-off from VUB (Vrije Universiteit Brussel), the company has evolved from a clinical-stage immunotherapy developer into a platform and tools company focused on strengthening its technology and manufacturing capabilities.[2]
The company serves pharmaceutical and biotech partners by providing proprietary mRNA-LNP (lipid nanoparticle) delivery platforms and RNA design services.[1] Rather than pursuing only internal drug development, eTheRNA has strategically repositioned to offer professional partnerships with companies at various stages—from startups to late-stage projects—leveraging decades of RNA expertise to accelerate pipeline development and resolve manufacturing challenges.[1] This shift reflects a recognition that its core competitive advantage lies in enabling technology rather than clinical execution alone.
eTheRNA was established in 2013 as an academic spin-off, grounding the company in rigorous scientific foundations.[2][3] The founding team brought deep expertise in RNA therapeutics and immunology, positioning the company to capitalize on the emerging potential of mRNA as a therapeutic modality—a field that would gain mainstream recognition following the COVID-19 pandemic success of Moderna and Pfizer vaccines.[2]
A pivotal moment came in February 2022, when eTheRNA signed a research agreement with Merck, the German pharmaceutical company, to jointly develop mRNA vaccines.[2] This partnership validated the company's platform technology and marked a transition point. Shortly thereafter, based on investor feedback, eTheRNA underwent a strategic reorientation in 2022, shifting from a traditional biotech model toward a platform-and-tools business model.[2] This decision reflected market realities: the company recognized greater value creation potential in enabling partners' mRNA programs rather than bearing the full risk and capital intensity of clinical development alone.
eTheRNA's competitive strengths center on proprietary technology depth and manufacturing expertise:
eTheRNA operates at the intersection of two powerful trends: the maturation of mRNA as a validated therapeutic modality and the growing demand for specialized biotech infrastructure.
The success of COVID-19 mRNA vaccines proved the technology's safety and efficacy at scale, transforming mRNA from academic curiosity to mainstream pharmaceutical tool.[2] However, this success created a bottleneck: numerous companies now seek to develop mRNA therapeutics but lack the specialized expertise in formulation, manufacturing, and sequence optimization. eTheRNA's pivot to a platform model positions it to capture value from this supply-demand imbalance.
The company also benefits from the broader biotech trend toward specialization and outsourcing. Rather than every mRNA program requiring in-house platform development, companies increasingly prefer to partner with specialized technology providers. eTheRNA's multi-office presence (Niel, Zwijnaarde, New York, Hong Kong) reflects ambitions to serve this global market.[2]
eTheRNA's strategic repositioning from a clinical-stage company to a platform provider is well-timed and defensible. As mRNA therapeutics proliferate across oncology, infectious disease, and rare genetic conditions, demand for differentiated delivery and formulation expertise will only intensify. The company's focus on manufacturing capabilities at its Niel site suggests confidence in long-term partnerships requiring reliable, scalable production.
The key question ahead is whether eTheRNA can maintain technological differentiation as larger pharma companies (Merck, Boehringer Ingelheim) and specialized CROs build competing capabilities. Success will depend on continuous innovation in LNP design, route-specific optimization, and the ability to solve manufacturing problems faster than competitors. If eTheRNA executes well, it could become an essential infrastructure layer in the mRNA therapeutics ecosystem—a position far more defensible than competing as a single-asset biotech company.